Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease

Y Zhang, A Hayes, A Pritchard, U Thaker, M S Haque, H Lemmon, J Harris, A Cumming, J C Lambert, M C Chartier-Harlin, D St Clair, T Iwatsubo, D M Mann, C L Lendon

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C - 174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n = 356) and controls (n = 434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (it = 338), brain amyloid load (it = 126) or Tau load (17 101), brain microglial cell load (n = 65) or brain reactive astrocytes (n = 127). Our data do not support a pathogenic role in AD for the C 174G polymorphism in isolation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalNeuroscience Letters
Issue number2
Early online date16 Apr 2004
Publication statusPublished - 20 May 2004


  • Alzheimer's disease
  • polymorphism
  • interleukin-6
  • promoter
  • brain
  • amyloid load
  • microglial cell load
  • reactive astrocytes
  • genetic polymorphisms
  • association
  • Beta
  • population
  • protein


Dive into the research topics of 'Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this